Drug
Golidocitinib clinical trials
Also written AZD4205.
- studies test it
- 33
- open now
- 26
- in phase 3
- 5
- first study started
- 2018
Keep track of what changes. Save the golidocitinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
33 studies that test it; most in 2025 (13)
| Year | Studies |
|---|---|
| 2018 | 2 |
| 2019 | 1 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 13 |
| 2026 | 9 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 14
- Phase 2
- 27
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 25
Dizal Pharmaceuticals (8) · Sun Yat-sen University (4) · Ruijin Hospital (4) · Peking Union Medical College Hospital (2) · Peking University Cancer Hospital & Institute (2) · Fudan University (2) · Beijing Friendship Hospital (2) · Washington University School of Medicine (1)
Often tested with
Tested in the same studies.
Tucidinostat (5) · Selinexor (2) · Sunvozertinib (1) · Carbamazepine (1) · Itraconazole (1) · Adrenal Cortex Hormones (1) · Zeprumetostat (1) · Decitabine (1)
Studies
Open first, then newest update. How each study uses golidocitinib is read from its arms, and is right about nine times in ten.
Testing it · 33
- A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative StudyRecruitingPhase 2M.D. Anderson Cancer CenterNCT06630091Written as Golidocitinib
- Golidocitinib and Chidamide for Cutaneous T-Cell LymphomaRecruitingPhase 1/2Peking Union Medical College HospitalNCT07754890Written as golidocitinib
- Golidocitinib Plus Anthracycline-based Therapy for Untreated Nodal T-follicular Helper (TFH) Cell LymphomaNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07753642Written as Golidocitinib
- Efficacy and Safety of Golidocitinib for Rapidly Progressive Interstitial Lung DiseaseNot yet recruitingPhase 2Peking Union Medical College HospitalNCT07737249Written as golidocitinib plus corticosteroid
- Golidocitinib in Patients With Mycosis Fungoides/Sézary Syndrome and T-Cell Large Granular Lymphocytic LeukemiaNot yet recruitingPhase 2Washington University School of MedicineNCT07682792Written as Golidocitinib
- A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)RecruitingPhase 3Dizal PharmaceuticalsNCT07234162Written as Golidocitinib
- Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)RecruitingPhase 1/2Beijing Tongren HospitalNCT07525466Written as golidocitinib
- Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCLNot yet recruitingPhase 1/2Ruijin HospitalNCT07493330Written as Zeprumetostat+Golidocitinib
- Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell LymphomaRecruitingPhase 3Fudan UniversityNCT07300514Written as golidocitinib
- Golidocitinib With PD-1 Inhibitors as Maintenance Treatment for Previously Untreated ES-SCLCRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07110103Written as golidocitinib with PD-1 inhibitors
- Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line ChemotherapyRecruitingPhase 3Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineNCT07414758Written as golidocitinib
- Golidocitinib Combined With Selinexor for CAEBVDRecruitingPhase 2/3Beijing Friendship HospitalNCT07369739Written as golidocitinib
- Prospective Single-Arm Clinical Trial of GO Regimen for HLH.RecruitingPhase 2/3Beijing Friendship HospitalNCT07339345Written as Golidocitinib
- Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell LymphomaRecruitingPhase 1/2Sun Yat-sen UniversityNCT07093710Written as Golidocitinib
- Golidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung CancerNot yet recruitingPhase 2The First Affiliated Hospital of Guangzhou Medical UniversityNCT07303881Written as golidocitinib
- Safety and Efficacy of the JAK1 Inhibitor Combined With Intensive Immunosuppressive Therapy in Severe Aplastic AnemiaNot yet recruitingPhase 1/2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07297550Written as Golidocitinib Capsules
- Golidocitinib Combined With GemOx in RR PTCLNot yet recruitingPhase 2Ruijin HospitalNCT07279584Written as golidocitinib
- Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell LymphomaNot yet recruitingPhase 1/2Ruijin HospitalNCT07209163Written as Golidocitinib
- An Exploratory Study of Golidocitinib in Adult Patients With ITPNot yet recruitingPhase 1/2Peking University People's HospitalNCT07196163Written as Golidocitinib
- Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.Not yet recruitingPhase 2Ruijin HospitalNCT07081607Written as golidocitinib with azacytidine and chidamide
See all 33 studies that test golidocitinib →
Given in every arm · 4 — golidocitinib is usual care beside what is tested
- PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCLRecruitingPhase 2Ruijin HospitalNCT07380984Written as golidocitinib
- EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell LymphomasNot yet recruitingPhase 1/2Sun Yat-sen UniversityNCT07339527Written as Golidocitinib
- Go-CHOP in de Novo Intestinal T-cell Lymphoma PatientsNot yet recruitingPhase 2Ruijin HospitalNCT06701344Written as Golidocitinib
- Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)Not yet recruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT06198907Written as Golidocitinib
Codes
What other systems call golidocitinib · ClinicalTrials.gg INT014641
- UNII (FDA) 3BY9Z3M34GGOLIDOCITINIBConfirmed FDA, Wikidata
- Wikidata Q131696536golidocitinibConfirmed FDA, Wikidata
- NCI Thesaurus C156774GolidocitinibOne source FDA
- DrugBank DB18057One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 3BY9Z3M34G | GOLIDOCITINIB | Confirmed FDA, Wikidata |
| Wikidata | Q131696536 | golidocitinib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C156774 | Golidocitinib | One source FDA |
| DrugBank | DB18057 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.